Hi Everyone:

Inspire Pharmaceuticals is excited about their new drug, Denufosol, that "is a first in-class ion channel regulator that addresses the underlying ion transport defect in the lungs of people with CF. Denufosol is designed to enhance airway hydration and mucociliary clearance by stimulating chloride secretion, inhibiting sodium absorption and increasing ciliary beat frequency."

Further, the European Respiratory Society presented research in September of this year that showed "denufosol significantly improves lung function, compared with placebo, in patients with mild CF who are on limited background therapies ..."

Denufosol was approved for orphan drug status in Europe in 2006.

When Phase III clinical trials are completed in the U.S. (hopefully by next summer), the results will be sent to the FDA for approval (hopefully within six months) and, if all goes well, the drug can possibly be on the market sometime in 2012.

This is creating some exciting 'buzz' according to our sources, and it looks like a very promising treatment at this point.

All the best,
Bob

Bob Derr, PACFI
www.pacfi.org